Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
AssigneeCuris, Inc.
InventorsThangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
Life of this patent
Estimating the term…
Abstract
The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.
Claims14
A method of treating osteopenia, comprising administering systemically to a mammal a composition consisting essentially of a morphogen and a pharmaceutically-acceptable vehicle, wherein said mammal suffers from osteopenia, and wherein said morphogen comprises an amino acid sequence selected from the group consisting of a sequence:
- (a) having at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 330-431 of SEQ ID NO:
- 5;
- (b) having greater than 60% amino acid sequence identity with said C-terminal seven-cysteine skeleton of human OP-1;
- and
- (c) defined by OPX, SEQ ID NO:
- 29,
- wherein said morphogen does not have the amino acid sequence of TGF-β2 and wherein said morphogen stimulates endochondral bone formation in an in vivo bone assay.
A method for restoring loss of bone mass in a mammal afflicted with osteopenia, comprising administering systemically to said mammal a composition consisting essentially of a morphogen and a pharmaceutically-acceptable vehicle, wherein said morphogen comprises an amino acid sequence selected from the group consisting of a sequence:
- (a) having at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 330-431 of SEQ ID NO:
- 5;
- (b) having greater than 60% amino acid sequence identity with said C-terminal seven-cysteine skeleton of human OP-1;
- and
- (c) defined by OPX, SEQ ID NO:
- 29,
- wherein said morphogen does not have the amino acid sequence of TGF-β2 and wherein said morphogen stimulates endochondral bone formation in an in vivo bone assay.
A method for preventing loss of bone mass in a mammal at risk of osteopenia, comprising administering systemically to said mammal a composition consisting essentially of a morphogen and a pharmaceutically-acceptable vehicle, wherein said morphogen comprises an amino acid sequence selected from the group consisting of a sequence:
- (a) having at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 330-431 of SEQ ID NO:
- 5;
- (b) having greater than 60% amino acid sequence identity with said C-terminal seven-cysteine skeleton of human OP-1;
- and
- (c) defined by OPX, SEQ ID NO:
- 29,
- wherein said morphogen does not have the amino acid sequence of TGF-β2 and wherein said morphogen stimulates endochondral bone formation in an in vivo bone assay, and wherein said mammal suffers from osteopenia.
A method of treating osteopenia, comprising administering systemically to a mammal suffering from osteopenia a composition consisting essentially of a morphogen and a pharmaceutically-acceptable vehicle, wherein said morphogen is selected from the group consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6, wherein said morphogen stimulates endochondral bone formation in an in vivo bone assay.
A method for restoring loss of bone mass in a mammal afflicted with osteopenia, comprising administering systemically to said mammal a composition consisting essentially of a morphogen and a pharmaceutically-acceptable vehicle, wherein said morphogen is selected from the group consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6, wherein said morphogen stimulates endochondral bone formation in an in vivo bone assay.
A method for preventing loss of bone mass in a mammal at risk of osteopenia, comprising administering systemically to said mammal a composition consisting essentially of a morphogen and a pharmaceutically-acceptable vehicle, wherein said morphogen is selected from the group consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6, wherein said morphogen stimulates endochondral bone formation in an in vivo bone assay.
Dependencies are inferred from the claim text.